Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giles Best

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Leukemia & Lymphoma|June 1, 2012
Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotypeO Giles Best, Stephen P Mulligan
Leukemia & Lymphoma|July 30, 2020
Combination of the dual PIM/PI3-kinase inhibitor IBL-202 and venetoclax is effective in diffuse large B-cell lymphomaGrace Gifford, William Stevenson, Giles Best
Leukemia & Lymphoma|May 10, 2012
Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemiaGiles Best, Philip Thompson, Constantine S Tam
World Journal of Clinical Cases|August 25, 2015
Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to dateKyle Crassini, Stephen P Mulligan, O Giles Best
Molecular and Cellular Biochemistry|April 29, 2009
The phosphorylation status of membrane-bound nucleoside diphosphate kinase in epithelia and the role of AMPKate J Treharne, Oliver Giles Best, Anil Mehta
FEBS Letters|July 22, 2009
Transglutaminase 2 and nucleoside diphosphate kinase activity are correlated in epithelial membranes and are abnormal in cystic fibrosisKate J Treharne, O Giles Best, Anil Mehta
Leukemia & Lymphoma|October 21, 2016
Modeling the chronic lymphocytic leukemia microenvironment in vitroKyle Crassini, Yandong Shen, Stephen Mulligan, et al.
Leukemia & Lymphoma|November 3, 2005
ZAP-70 in B cell malignanciesJenny Orchard, Rachel Ibbotson, Giles Best, et al.
British Journal of Haematology|August 27, 2010
The novel Hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathwayO Giles Best, Nisha Singh, Cecily Forsyth, et al.
Leukemia & Lymphoma|November 7, 2023
The effect of HYPE knock-out on the AMPylome of human OSU-CLL leukemia cellsNarjis Fatima, O Giles Best, Larissa Belov, et al.
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Leukemia & Lymphoma|June 1, 2012
Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotypeO Giles Best, Stephen P Mulligan
Leukemia & Lymphoma|July 30, 2020
Combination of the dual PIM/PI3-kinase inhibitor IBL-202 and venetoclax is effective in diffuse large B-cell lymphomaGrace Gifford, William Stevenson, Giles Best
Leukemia & Lymphoma|May 10, 2012
Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemiaGiles Best, Philip Thompson, Constantine S Tam
World Journal of Clinical Cases|August 25, 2015
Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to dateKyle Crassini, Stephen P Mulligan, O Giles Best
Molecular and Cellular Biochemistry|April 29, 2009
The phosphorylation status of membrane-bound nucleoside diphosphate kinase in epithelia and the role of AMPKate J Treharne, Oliver Giles Best, Anil Mehta
FEBS Letters|July 22, 2009
Transglutaminase 2 and nucleoside diphosphate kinase activity are correlated in epithelial membranes and are abnormal in cystic fibrosisKate J Treharne, O Giles Best, Anil Mehta
Leukemia & Lymphoma|October 21, 2016
Modeling the chronic lymphocytic leukemia microenvironment in vitroKyle Crassini, Yandong Shen, Stephen Mulligan, et al.
Leukemia & Lymphoma|November 3, 2005
ZAP-70 in B cell malignanciesJenny Orchard, Rachel Ibbotson, Giles Best, et al.
British Journal of Haematology|August 27, 2010
The novel Hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathwayO Giles Best, Nisha Singh, Cecily Forsyth, et al.
Leukemia & Lymphoma|November 7, 2023
The effect of HYPE knock-out on the AMPylome of human OSU-CLL leukemia cellsNarjis Fatima, O Giles Best, Larissa Belov, et al.
Pageof 7